pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
11989B | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11989B | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11989B | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11989B | upadacitinib | Rinvoq | Tablet 15 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5753T | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
9673D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9673D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9673D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9673D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9673D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
9673D | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
10064Q | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
12553Q | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | rheumatoid arthritis | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11443G | baricitinib | Olumiant | Tablet 4 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11443G | baricitinib | Olumiant | Tablet 4 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Brenzys | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9085E | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | ankylosing spondylitis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
5735W | etanercept | Enbrel | Injection 50 mg in 1 mL single use auto-injector, 4 | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11497D | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11497D | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11497D | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
11483J | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | 14505 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11483J | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | 14505 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
11483J | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Subsequent continuing treatment | 14505 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
13338B | tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | juvenile idiopathic arthritis | Continuing treatment | 14082 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |